![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Objective: The aim of this study was to investigate the association between anti-angiogenic factor soluble c-Met (sMet) concentrations in maternal plasma and the risk of preeclampsia.
Methods: The pregnant women included in this study (1) had subsequent preeclampsia (n = 52) and were compared to normal controls (n = 104) at the time of amniocentesis (15–20 weeks); and (2) had preeclampsia (n = 63) and were compared to normal controls (n = 112) at the time of diagnosis of preeclampsia (29–40 weeks). sMet concentrations were measured by ELISA. Non-parametric statistics were used for analysis.
Results: Maternal plasma sMet concentrations were significantly higher in both women with subsequent preeclampsia (median: 1372.7 ng/ml versus 1100.5 ng/ml; p = 0.036) and women with preeclampsia (median: 1651.9 ng/ml versus 1364.7 ng/ml; p < 0.001) than in the controls. After adjusting for potential confounding factors, the risks of developing preeclampsia were as follows: adjusted odds ratio 2.5 (95% confidence interval, 1.2–5.2; p = 0.016) for second trimester sMet concentration with a cut-off value of 1223.5 ng/ml and 4.4 (95% confidence interval, 2.2–9.1; p < 0.001) for third trimester sMet concentration with a cut-off value of 1460.3 ng/ml.
Conclusion: Elevated maternal plasma sMet concentrations were independently associated with the increased risk of preeclampsia.